Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis

Arthritis Research and Therapy

Volumn 11, Issue 4, 2009, Pages

  van der Heijde, Désirée M ^a   Revicki, Dennis A ^b   Gooch, Katherine L ^c   Wong, Robert L ^c   Kupper, Hartmut ^d   Harnam, Neesha ^b   Thompson, Chris ^b   Sieper, Joachim ^e  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNITED BIOSOURCE CORPORATION   (United States)

^c ABBOTT LABORATORIES   (United States)

^d ABBOTT GMBH AND CO KG   (Germany)

^e German Rheumatism Research Center   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; PLACEBO; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ANKYLOSING SPONDYLITIS; ANKYLOSING SPONDYLITIS QUALITY OF LIFE QUESTIONNAIRE; ARTICLE; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; BATH ANKYLOSING SPONDYLITIS FUNCTIONAL INDEX; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FUNCTIONAL STATUS; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PHYSICAL ACTIVITY; QUALITY OF LIFE; QUALITY OF LIFE INDEX; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; SHORT FORM 36; TREATMENT DURATION; HOSPITALIZATION; PSYCHOLOGICAL ASPECT; QUESTIONNAIRE; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; QUALITY OF LIFE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME;

EID: 69849083250     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2790     Document Type: Article

References (47)

1. Gran JT Husby G The epidemiology of ankylosing spondylitis Semin Arthritis Rheum 1993, 22:319-334 10.1016/S0049-0172(05)80011-3 8511596
2. Dagfinrud H Mengshoel AM Hagan KB Loge JH Kvien TK Health status of patients with ankylosing spondylitis: A comparison with the general population Ann Rheum Dis 2004, 63:1605-1610 10.1136/ard.2003.019224 1754848 15547084
3. Bostan EE Borman P Bodur H Functional disability and quality of life in patients with ankylosing spondylitis Rheumatol Int 2003, 23:121-126 12739042
4. Zink A Braun J Listing J Wollenhaupt J Disability and handicap in rheumatoid arthritis and ankylosing spondylitis: Results from the German rheumatological database J Rheumatol 2000, 27:613-622 10743798
5. Ward MM Quality of life in patients with ankylosing spondylitis Rheum Dis Clin North Am 1998, 24:815-827 10.1016/S0889-857X(05)70043-0 9891712
6. Ware JE Jr Snow KK Kosinski M SF-36 Health Survey: Manual and Interpretation Guide Lincoln, RI: Quality Metric 2000.
7. Doward LC Spoorenberg A Cook SA Whalley D Helliwell PS Kay LF McKenna SP Tennant A Heijde van der D Chamberlain MA Development of the ASQoL: A quality of life instrument specific to ankylosing spondylitis Ann Rheum Dis 2003, 62:20-26 10.1136/ard.62.1.20 1754293 12480664
8. Baraliakos X Listing J Brandt J Zink A Alten R Burmester G Gromnica-Ihle E Kellner H Schneider M Sörensen H Zeidler H Rudwaleit M Sieper J Braun J Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab Arthritis Res Ther 2005, 7:R439-R444 10.1186/ ar1693 1174938 15899030
9. Boonen A Heijde van der D Landewe R van Tubergen A Mielants H Dougados M Linden van der S How do the EQ-5D, SF-6D and the well-being rating scale compare in patients with ankylosing spondylitis? Ann Rheum Dis 2007, 66:771-777 10.1136/ard.2006.060384 17213254
10. Brandt J Listing J Haibel H Sorensen H Schwebig A Rudwaleit M Sieper J Braun J Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis Rheumatology (Oxford) 2005, 44:342-348 10.1093/rheumatology/keh475 15561737
11. Braun J Baraliakos X Brandt J Listing J Zink A Alten R Burmester G Gromnica-Ihle E Kellner H Schneider M Sörensen H Zeidler H Sieper J Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years Rheumatology (Oxford) 2005, 44:670-676 10.1093/rheumatology/keh584 15757965
12. Braun J McHugh N Singh A Wajdula JS Sato R Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly Rheumatology (Oxford) 2007, 46:999-1004 10.1093/rheumatology/kem069 17389658
13. Haibel H Rudwaleit M Braun J Sieper J Six months open label trial of leflunomide in active ankylosing spondylitis Ann Rheum Dis 2005, 64:124-126 10.1136/ard.2003.019174 1755172 15608310
14. Heijde van der D Baraf HS Ramos-Remus C Calin A Weaver AL Schiff M James M Markind JE Reicin AS Melian A Dougados M Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: Results of a fifty-two-week, randomized, controlled study Arthritis Rheum 2005, 52:1205-1215 10.1002/ art.20985 15818702
15. Heijde van der D Dijkmans B Geusens P Sieper J DeWoody K Williamson P Braun J Efficacy and safety of infliximab in patients with ankylosing spondylitis: Results of a randomized, placebo-controlled trial (ASSERT) Arthritis Rheum 2005, 52:582-591 10.1002/art.20852 15692973
16. Davis JC Revicki D Heijde van der DMF Rentz AM Wong RL Kupper H Luo MP Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: Results from a randomized controlled study Arthritis Rheum 2007, 57:1050-1057 10.1002/ art.22887 17665483
17. Revicki DA Luo MP Wordsworth P Wong RL Chen N Davis JC Adalimumab reduces pain, fatigue, and stiffness in patients with ankylosing spondylitis: Results from the Adalimumab Trial Evaluating Long-Term Safety and Efficacy for Ankylosing Spondylitis (ATLAS) J Rheumatol 2008, 35:1346-1353 18484692
18. Braun J Deodhar A Dijkmans B Geusens P Sieper J Williamson P Xu W Visvanathan S Baker D Goldstein N Heijde van der D Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period Arthritis Rheum 2008, 59:1270-1278 10.1002/art.24001 18759257
19. Boonen A Patel V Traina S Chiou C-F Maetzel A Tsuji W Rapid and sustained improvement in health-related quality of life and utility 72 weeks in patients with ankylosing spondylitis receiving etanercept J Rheumatol 2008, 35:662-667 18278836
20. Marzo-Ortega H McGonagle D Jarrett S Haugeberg G Hensor E O'Connor P Tan AL Conaghan PG Greenstein A Emery P Infliximab in combination with methotrexate in active ankylosing spondylitis: A clinical and imaging study Ann Rheum Dis 2005, 64:1568-1575 10.1136/ard.2004.022582 1755262 15829577
21. Zhao LK Liao ZT Li CH Li TW Wu J Lin Q Huang F Yu DT Gu JR Evaluation of quality of life using ASQOL questionnaire in patients with ankylosing spondylitis in a Chinese population Rheumatol Int 2007, 27:605-611 10.1007/s00296-006-0267-4 17103172
22. Davis JC Heijde van der D Dougados M Woolley JM Reductions in health-related quality of life in patients with ankylosing spondylitis and improvements with etanercept therapy Arthritis Rheum 2005, 53:494-501 10.1002/art.21330 16082640
23. Braun J Sieper J Ankylosing spondylitis Lancet 2007, 369:1379-1390 10.1016/S0140-6736(07)60635-7 17448825
24. Baraliakos X Listing J Rudwaleit M Brandt J Alten R Burmester G Gromnica-Ihle E Haibel H Schewe S Schneider M Sörensen H Zeidler H Visvanathan S Sieper J Braun J Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis J Rheumatol 2007, 34:510-515 17299842
25. Baraliakos X Brandt J Listing J Haibel H Sorensen H Rudwaleit M Sieper J Braun J Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: Clinical and magnetic resonance imaging data Arthritis Rheum 2005, 53:856-863 10.1002/art.21588 16342093
26. Cantini F Niccoli L Benucci M Chindamo D Nannini C Olivieri I Padula A Salvarani C Switching from infliximab to once-weekly administration of 50 mg etanercept in resistant or intolerant patients with ankylosing spondylitis: Results of a fifty-four-week study Arthritis Rheum 2006, 55:812-816 10.1002/art.22236 17013842
27. Perez-Guijo VC Cravo AR Castro Mdel C Font P Munoz-Gomariz E Collantes-Estevez E Increased efficacy of infliximab associated with methotrexate in ankylosing spondylitis Joint Bone Spine 2007, 74:254-258 10.1016/j.jbspin.2006.08.005 17387031
28. Gadsby K Deighton C Characteristics and treatment responses of patients satisfying the BSR guidelines for anti-TNF in ankylosing spondylitis Rheumatology (Oxford) 2007, 46:439-441 10.1093/rheumatology/kel430 17255137
29. Jois RN Leeder J Gibb A Gaffney K Macgregor A Somerville M Scott DG Low-dose infliximab treatment for ankylosing spondylitis - clinically- and cost-effective Rheumatology (Oxford) 2006, 45:1566-1569 10.1093/ rheumatology/kel156 16705043
30. Keeling S Oswald A Russell AS Maksymowych WP Prospective observational analysis of the efficacy and safety of low-dose (3 mg/kg) infliximab in ankylosing spondylitis: 4-year follow-up J Rheumatol 2006, 33:558-561 16463437
31. Heijde van der D Da Silva JC Dougados M Geher P Horst-Bruinsma van der I Juanola X Olivieri I Raeman F Settas L Sieper J Szechinski J Walker D Boussuge MP Wajdula JS Paolozzi L Fatenejad S Etanercept Study 314 Investigators Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis Ann Rheum Dis 2006, 65:1572-1577 10.1136/ard.2006.056747 16968715
32. Heijde van der D Kivitz A Schiff MH Sieper J Dijkmans BA Braun J Dougados M Reveille JD Wong RL Kupper H Davis JC Jr ATLAS Study Group Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double-blind, placebo-controlled trial Arthritis Rheum 2006, 54:2136-2146 10.1002/ art.21913 16802350
33. Heijde van der D Schiff MH Sieper J Kivitz A Wong RL Kupper H Dijkmans BA Mease PJ Davis JC Jr ATLAS Study Group Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial Ann Rheum Dis 2009, 68:922-929 10.1136/ard.2007.087270 2674550 18701556
34. Linden van der S Valkenburg HA Cats A Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria Arthritis Rheum 1984, 27:361-368 10.1002/art.1780270401 6231933
35. Calin A Garrett S Whitelock H Kennedy LG O'Hea J Mallorie P Jenkinson T A new approach to defining functional ability in ankylosing spondylitis: The development of the Bath Ankylosing Spondylitis Functional Index J Rheumatol 1994, 21:2281-2285 7699629
36. Garrett S Jenkinson T Kennedy LG Whitelock H Gaisford P Calin A A new approach to defining disease status in ankylosing spondylitis: The Bath Ankylosing Spondylitis Disease Activity Index J Rheumatol 1994, 21:2286-2291 7699630
37. Ruof J Sangha O Stucki G Comparative responsiveness of 3 functional indices in ankylosing spondylitis J Rheumatol 1999, 26:1959-1963 10493677
38. Pavy S Brophy S Calin A Establishment of the minimum clinically important difference for the Bath Ankylosing Spondylitis Indices: A prospective study J Rheumatol 2005, 32:80-85 15630730
39. Auleley G Benbouazza K Spoorenberg A Collantes E Hajjaj-Hassouni N Heijde van der D Dougados M Evaluation of the smallest detectable difference in outcome or process variables in ankylosing spondylitis Arthritis Rheum 2002, 47:582-587 10.1002/art.10798 12522830
40. Stone MA Inman RD Wright JG Maetzel A Validation exercise of the Ankylosing Spondylitis Assessment Study (ASAS) group response criteria in ankylosing spondylitis patients treated with biologics Arthritis Rheum 2004, 51:316-320 10.1002/art.20414 15188313
41. Kosinski M Zhao SZ Dedhiya S Osterhaus JT Ware JE Jr Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis Arthritis Rheum 2000, 43:1478-1487 10.1002/ 1529-0131(200007)43:7<1478::AID-ANR10>3.0.CO;2-M 10902749
42. Haywood KL Garratt AM Jordan K Dziedzic K Dawes PT Disease-specific, patient-assessed measures of health outcome in ankylosing spondylitis: reliability, validity and responsiveness Rheumatology 2002, 41:1295-1302 10.1093/rheumatology/41.11.1295 12422003
43. Haywood KL Garratt AM Dziedzic K Dawes PT Patient centered assessment of ankylosing spondylitis-specific health related quality of life: evaluation of the patient generated index J Rheumatol 2003, 30:764-773 12672197
44. Kazis LE Anderson JJ Meenan RF Effect sizes for interpreting changes in health status Med Care 1989, 27:S178-S189 10.1097/ 00005650-198903001-00015 2646488
45. Cohen J The effect size Statistical Power Analysis for the Behavioral Sciences New York: Academic Press 1977 8-13
46. Revicki D Hays RD Cella D Sloan J Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes J Clin Epidemiol 2008, 61:102-109 10.1016/ j.jclinepi.2007.03.012 18177782
47. Haibel H Rudwaleit M Brandt HC Grozdanovic Z Listing J Kupper H Braun J Sieper J Adalimumab reduces spinal symptoms in active ankylosing spondylitis: Clinical and magnetic resonance imaging results of a fifty-two-week open-label trial Arthritis Rheum 2006, 54:678-681 10.1002/ art.21563 16447247